{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:50:39Z","timestamp":1790725839250,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ctrv.2025.103083","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T19:12:19Z","timestamp":1767208339000},"page":"103083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2879-5346","authenticated-orcid":false,"given":"Seng Wee","family":"Cheo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly S.C.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek De-Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie P.L.","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Menis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Jye","family":"Voon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.103083_b0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejca.2020.03.006","article-title":"Systemic treatment of brain metastases in non-small cell lung cancer","volume":"132","author":"Page","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.103083_b0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ctrv.2016.03.009","article-title":"The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer","volume":"45","author":"Peters","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2025.103083_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102807","article-title":"Central nervous system metastases in advanced non-small cell lung cancer: a review of the therapeutic landscape","volume":"130","author":"Weller","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2025.103083_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102393","article-title":"A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)","volume":"106","author":"Abuhelwa","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103083_b0025","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.3390\/cancers15061845","article-title":"Target Antigen Attributes and their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers","volume":"15","author":"Esapa","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103083_b0030","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/14712598.2021.1880562","article-title":"What makes a good antibody-drug conjugate?","volume":"21","author":"De Cecco","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103083_b0035","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11523-017-0535-0","article-title":"Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and latest Developments","volume":"12","author":"Nagayama","year":"2017","journal-title":"Target Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103083_b0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103083_b0045","first-page":"4744","article-title":"Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells","volume":"61","author":"Molina","year":"2001","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103083_b0050","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103083_b0055","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ctrv.2014.03.005","article-title":"Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases","volume":"40","author":"Zimmermann","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"120","key":"10.1016\/j.ctrv.2025.103083_b0060","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neuropharm.2016.03.014","article-title":"Antibody therapies in CNS diseases","volume":"1","author":"Freskg\u00e5rd","year":"2017","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103083_b0065","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1158\/1535-7163.MCT-19-0022","article-title":"Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: a Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer","volume":"18","author":"Whalen","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103083_b0070","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3390\/cancers17091591","article-title":"Exploring the Role of ADCs in Brain Metastases and Primary Brain Tumors: Insight and Future Directions","volume":"17","author":"Bruzzone","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2025.103083_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110839","article-title":"Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors","author":"Anami","year":"2022","journal-title":"Cell Reports [Internet]"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103083_b0080","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41571-023-00756-z","article-title":"Understanding the activity of antibody\u2013drug conjugates in primary and secondary brain tumours","volume":"20","author":"Mair","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103083_b0085","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC Toxicity and strategies to increase ADC Tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103083_b0090","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.annonc.2020.06.021","article-title":"Reevaluating the role of antibody-drug conjugates in the treatment of patients with brain metastases","volume":"31","author":"Lin","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103083_b0095","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2025.103083_b0100","article-title":"Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress","volume":"43","author":"Rosner","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103083_b0105","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/ijms26010221","article-title":"Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: State of the Art and Future Perspectives","volume":"26","author":"Zanchetta","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"17","key":"10.1016\/j.ctrv.2025.103083_b0110","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.3390\/cancers14174155","article-title":"HER2 in Non-Small Cell Lung Cancer: a Review of Emerging Therapies","volume":"14","author":"Uy","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.ctrv.2025.103083_b0115","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1002\/cncr.32461","article-title":"Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers","volume":"125","author":"Offin","year":"2019","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.ctrv.2025.103083_b0120","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103083_b0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.ctrv.2025.103083_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab deruxtecan in breast cancer","volume":"198","author":"Mart\u00edn","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"31","key":"10.1016\/j.ctrv.2025.103083_b0135","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab Deruxtecan in patients with HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary results from the Randomized, phase II DESTINY-Lung02 Trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103083_b0140","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103083_b0145","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103083_b0150","doi-asserted-by":"crossref","unstructured":"Planchard D, Kim HR, Suksombooncharoen T, Li R, Samol J, Runglodvatana Y, et al. OA16.05 Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-overexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1. Journal of Thoracic Oncology. 2024 Oct 1;19(10, Supplement):S46\u20137.","DOI":"10.1016\/j.jtho.2024.09.082"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103083_b0155","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1078-0432.CCR-23-2566","article-title":"TROP2 is Associated with Primary Resistance to Immune Checkpoint Inhibition in patients with Advanced Non-Small Cell Lung Cancer","volume":"30","author":"Bessede","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.ctrv.2025.103083_b0160","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.2147\/DDDT.S489234","article-title":"Current Status and Future prospects of TROP-2 ADCs in Lung Cancer Treatment","volume":"6","author":"Li","year":"2024","journal-title":"Drug Des Devel Ther"},{"issue":"24","key":"10.1016\/j.ctrv.2025.103083_b0165","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.24.01043","article-title":"TROP2-Directed Antibody-Drug Conjugates in Advanced Non-Small Cell Lung Cancer: a Fading Hope?","volume":"42","author":"P\u00e9rol","year":"2024","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.ctrv.2025.103083_b0170","doi-asserted-by":"crossref","first-page":"S810","DOI":"10.1016\/j.annonc.2023.09.2450","article-title":"1419P TACSTD2 (Trop-2) constitutes a promising antibody-drug conjugate target for patients with non-small cell lung cancer brain metastases","volume":"1","author":"Hijazo-Pechero","year":"2023","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103083_b0175","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor activity by Efficient Drug delivery to Tumor Cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103083_b0180","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab Deruxtecan Versus Docetaxel for previously Treated Advanced or Metastatic Non\u2013Small Cell Lung Cancer: the Randomized, Open-Label phase III TROPION-Lung01 Study","volume":"43","author":"Ahn","year":"2025","journal-title":"JCO"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103083_b0185","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer with Actionable Genomic Alterations: results from the phase II TROPION-Lung05 Study","volume":"43","author":"Sands","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103083_b0190","doi-asserted-by":"crossref","unstructured":"Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, et al. A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC. Journal of Thoracic Oncology [Internet]. [cited 2025 Oct 24]; Available from: https:\/\/doi.org\/10.1016\/j.jtho.2025.06.002.","DOI":"10.1016\/j.jtho.2025.06.002"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103083_b0195","article-title":"Targeting MET in NSCLC: an Ever-Expanding Territory","volume":"5","author":"Han","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.ctrv.2025.103083_b0200","article-title":"CNS Metastases in patients with MET Exon 14-Altered Lung Cancers and Outcomes with Crizotinib. JCO Precis","volume":"4","author":"Offin","year":"2020","journal-title":"Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103083_b0205","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2353\/ajpath.2010.090863","article-title":"Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis","volume":"177","author":"Benedettini","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2025.103083_b0210","article-title":"Telisotuzumab Vedotin Monotherapy in patients with previously Treated c-Met Protein\u2013Overexpressing Advanced Nonsquamous EGFR-Wildtype Non\u2013Small Cell Lung Cancer in the phase II LUMINOSITY Trial","author":"Camidge","year":"2024","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.ctrv.2025.103083_b0215","doi-asserted-by":"crossref","first-page":"S762","DOI":"10.1016\/j.annonc.2023.09.2354","article-title":"1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non\u2013small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02","volume":"1","author":"Li","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103083_b0250","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1470-2045(25)00012-9","article-title":"Trastuzumab rezetecan, a HER2-directed antibody\u2013drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study","volume":"26","author":"Li","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.103083_b0490","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-023-00522-5","article-title":"Phase I study of A166, an antibody\u2012drug conjugate in advanced HER2-expressing solid tumours","author":"Zhang","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2025.103083_b0495","unstructured":"Doherty K. Dato-DXd Leads to Intracranial Responses in Advanced\/Metastatic NSCLC With Brain Metastases | OncLive [Internet]. 2025 [cited 2025 Sept 15]. Available from: https:\/\/www.onclive.com\/view\/dato-dxd-leads-to-intracranial-responses-in-advanced-metastatic-nsclc-with-brain-metastases."},{"issue":"35","key":"10.1016\/j.ctrv.2025.103083_b0260","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth factor Receptor-Mutated Non-Small-Cell Lung Cancer after Epidermal Growth factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-based Chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103083_b0295","doi-asserted-by":"crossref","unstructured":"Lisberg A, Lu S, Hamilton EP, Wang Q, Rotow JK, Starodub A, et al. DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: Preliminary results from the phase 1\/2a trial. JCO. 2025 June 1;43(16_suppl):3000\u20133000.","DOI":"10.1200\/JCO.2025.43.16_suppl.3000"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103083_b0310","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2\/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug Chem"},{"issue":"24","key":"10.1016\/j.ctrv.2025.103083_b0315","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","article-title":"Therapy of Advanced Non-Small-Cell Lung Cancer with an SN-38-Anti-Trop-2 Drug Conjugate","volume":"35","author":"Heist","year":"2017","journal-title":"Sacituzumab Govitecan J Clin Oncol"},{"issue":"389","key":"10.1016\/j.ctrv.2025.103083_b0345","article-title":"Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial","volume":"5","author":"Fang","year":"2025","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103083_b0265","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","article-title":"Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103083_b0300","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.3390\/curroncol31100471","article-title":"Antibody-Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central nervous System Metastases","volume":"31","author":"Bian","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2025.103083_b0275","doi-asserted-by":"crossref","unstructured":"Mok TSK, Yu HA, Lim SM, Okamoto I, Perol M, Novello S, et al. Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. JCO. 2025 June 1;43(16_suppl):8506\u20138506.","DOI":"10.1200\/JCO.2025.43.16_suppl.8506"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103083_b0320","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S1556-0864(25)00208-4","article-title":"13P: Brain metastases and actionable genetic alterations with sacituzumab govitecan versus docetaxel in metastatic non-small cell lung cancer: Subgroups of the phase III EVOKE-01 trial","volume":"20","author":"Felip","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2025.103083_b0325","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab Govitecan Versus Docetaxel for previously Treated Advanced or Metastatic Non\u2013Small Cell Lung Cancer: the Randomized, Open-Label phase III EVOKE-01 Study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103083_b0500","doi-asserted-by":"crossref","unstructured":"Fang W, Wang Q, Cheng Y, Luo Y, Qu X, Zhu H, et al. Sacituzumab tirumotecan (SKB264\/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study. JCO. 2024 June;42(16_suppl):8502\u20138502.","DOI":"10.1200\/JCO.2024.42.16_suppl.8502"},{"key":"10.1016\/j.ctrv.2025.103083_b0230","doi-asserted-by":"crossref","unstructured":"Lisberg A, Ahn MJ, Kitazono S, Cho BC, Blumenschein GR, Shum E, et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced\/metastatic non-small cell lung cancer (a\/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. JCO. 2024 June;42(16_suppl):8593\u20138593.","DOI":"10.1200\/JCO.2024.42.16_suppl.8593"},{"key":"10.1016\/j.ctrv.2025.103083_b0350","article-title":"21];0(0)","author":"Fang Wenfeng","year":"2025","journal-title":"Available from:"},{"key":"10.1016\/j.ctrv.2025.103083_b0360","doi-asserted-by":"crossref","unstructured":"Camidge DR, Raimbourg J, Lee YG, de Miguel MJ, Hollebecque A, Kim TM, et al. Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein\u2013targeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR-mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase 1 study. JCO. 2025 June 1;43(16_suppl):8512\u20138512.","DOI":"10.1200\/JCO.2025.43.16_suppl.8512"},{"key":"10.1016\/j.ctrv.2025.103083_b0220","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-1911","article-title":"Abstract 1911: Dato-DXd mediates anti-tumor activity in preclinical TROP2-expressing intracranial tumor model","author":"Jones","year":"2024","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103083_b0225","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jtho.2025.09.061","article-title":"OA10.01 Intracranial Efficacy of Datopotamab Deruxtecan (Dato-DXd) in patients with Advanced\/Metastatic NSCLC in TROPION-Lung01","volume":"20","author":"Pons-Tostivint","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103083_b0235","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.annonc.2025.01.001","article-title":"Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib","volume":"36","author":"Horinouchi","year":"2025","journal-title":"Ann Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2025.103083_b0240","article-title":"Use of Antibody\u2013Drug Conjugates in the Early setting of Breast Cancer","volume":"17","author":"Koukoutzeli","year":"2024","journal-title":"Clin Med Insights Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103083_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0326691","article-title":"SHR-A1811, a novel anti-HER2 antibody-drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles","volume":"20","author":"Zhang","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2025.103083_b0255","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.1017","article-title":"HER2-ADC trastuzumab rezetecan (SHR-A1811) in HER2-positive breast cancer with brain metastases: Update results from REIN trial","author":"Yan","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ctrv.2025.103083_b0270","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1158\/1078-0432.CCR-23-0020","article-title":"Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer","volume":"29","author":"Tomasich","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.ctrv.2025.103083_b0280","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1200\/JCO-24-02744","article-title":"Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer after Platinum-based Chemotherapy and Immunotherapy","volume":"43","author":"Steuer","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103083_b0285","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/neuonc\/noae123","article-title":"Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases","volume":"26","author":"Bartsch","year":"2024","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103083_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.08.001","article-title":"The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis","volume":"6","author":"Vaz Batista","year":"2025","journal-title":"Med"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103083_b0305","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103083_b0330","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.1038\/s41467-024-50558-9","article-title":"Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial","volume":"15","author":"Balinda","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2025.103083_b0335","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.951589","article-title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"12","author":"Cheng","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2025.103083_b0340","doi-asserted-by":"crossref","unstructured":"Fang W, Cheng Y, Chen Z, Wang W, Yin Y, Li Y, et al. SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study. JCO. 2023 June;41(16_suppl):9114\u20139114.","DOI":"10.1200\/JCO.2023.41.16_suppl.9114"},{"key":"10.1016\/j.ctrv.2025.103083_b0355","doi-asserted-by":"crossref","unstructured":"Abstract 6311: ABBV-400: An ADC delivering a novel topoisomerase 1 inhibitor to c-Met-positive solid tumors | Cancer Research | American Association for Cancer Research [Internet]. [cited 2025 Sept 15]. Available from: https:\/\/aacrjournals.org\/cancerres\/article\/83\/7_Supplement\/6311\/721017\/Abstract-6311-ABBV-400-An-ADC-delivering-a-novel.","DOI":"10.1158\/1538-7445.AM2023-6311"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103083_b0365","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jtho.2024.09.050","article-title":"OA08.05 Tusamitamab Ravtansine vs Docetaxel in previously Treated Advanced Nonsquamous NSCLC: results from phase 3 CARMEN-LC03 Trial","volume":"19","author":"Besse","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2025.103083_b0370","doi-asserted-by":"crossref","unstructured":"Gazzah A, Ricordel C, Cousin S, Cho BC, Calvo E, Kim TM, et al. Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). JCO. 2020 May 20;38(15_suppl):9505\u20139505.","DOI":"10.1200\/JCO.2020.38.15_suppl.9505"},{"key":"10.1016\/j.ctrv.2025.103083_b0375","doi-asserted-by":"crossref","unstructured":"Peters S, Hollebecque A, Sehgal K, Lopez JS, Calvo E, Dowlati A, et al. Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001). JCO. 2024 June;42(16_suppl):8521\u20138521.","DOI":"10.1200\/JCO.2024.42.16_suppl.8521"},{"key":"10.1016\/j.ctrv.2025.103083_b0380","doi-asserted-by":"crossref","unstructured":"Muro K, Feinstein T, Baranda J, Bonta I, Yanagitani N, Gersten T, et al. Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1\/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study. Eur J Cancer. 2025 Sept 9;227:115603.","DOI":"10.1016\/j.ejca.2025.115603"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103083_b0385","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ccell.2023.12.018","article-title":"Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms","volume":"42","author":"Bejarano","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103083_b0390","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/S1470-2045(17)30693-9","article-title":"Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group","volume":"19","author":"Camidge","year":"2018","journal-title":"Lancet Oncol"},{"issue":"33","key":"10.1016\/j.ctrv.2025.103083_b0395","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1200\/JCO.2017.74.0761","article-title":"Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology\u2013Friends of Cancer Research Brain Metastases Working Group","volume":"35","author":"Lin","year":"2017","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2025.103083_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114202","article-title":"\u201cSymptomatic\u201d melanoma brain metastases: a call for clear definitions and adoption of standardized tools","volume":"208","author":"Le Rhun","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2025.103083_b0405","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/EDBK_349155","article-title":"Extending our Reach: Expanding Enrollment in Brain Metastases and Primary Brain Tumor Clinical Trials","volume":"42","author":"Lee","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103083_b0410","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2217\/fon.13.271","article-title":"Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression?","volume":"10","author":"Walker","year":"2014","journal-title":"Future Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103083_b0415","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103083_b0420","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jamaoncol.2023.4492","article-title":"Symptomatic Necrosis with Antibody-Drug Conjugates and concurrent Stereotactic Radiotherapy for Brain Metastases","volume":"9","author":"Lebow","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2025.103083_b0425","doi-asserted-by":"crossref","DOI":"10.1093\/noajnl\/vdad118","article-title":"Evolution and implementation of radiographic response criteria in neuro-oncology","author":"Ramakrishnan","year":"2023","journal-title":"Neuro-Oncol Adv"},{"key":"10.1016\/j.ctrv.2025.103083_b0430","article-title":"Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. CNS","author":"Chukwueke","year":"2019","journal-title":"Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103083_b0435","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/s41591-025-03633-7","article-title":"RANO criteria for response assessment of brain metastases based on amino acid PET imaging","volume":"31","author":"Albert","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103083_b0440","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/neuonc\/noaa030","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases","volume":"22","author":"Kaufmann","year":"2020","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103083_b0445","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-473916","article-title":"Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell Therapies","volume":"45","author":"Jain","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ctrv.2025.103083_b0450","doi-asserted-by":"crossref","unstructured":"Fu Z, Gao C, Wu T, Wang L, Li S, Zhang Y, et al. Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates. iScience. 2023 Oct 20;26(10):107778.","DOI":"10.1016\/j.isci.2023.107778"},{"issue":"15","key":"10.1016\/j.ctrv.2025.103083_b0455","article-title":"A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)","volume":"7","author":"Tang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103083_b0460","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11060-024-04681-8","article-title":"Impact of concurrent antibody-drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study","volume":"168","author":"Koide","year":"2024","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2025.103083_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109805","article-title":"Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: a systematic review and meta-analysis","volume":"186","author":"Salvestrini","year":"2023","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103083_b0470","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/cpt.2291","article-title":"Exposure-Response Relationships in patients with HER2-positive Metastatic Breast Cancer and Other Solid Tumors Treated with Trastuzumab Deruxtecan","volume":"110","author":"Yin","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2025.103083_b0475","unstructured":"Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. 2018."},{"key":"10.1016\/j.ctrv.2025.103083_b0480","doi-asserted-by":"crossref","unstructured":"Coleman N, Yap TA, Heymach JV, Meric-Bernstam F, Le X. Antibody-drug conjugates in lung cancer: dawn of a new era? npj Precision Oncology. 2023 Jan 11;7(1):5.","DOI":"10.1038\/s41698-022-00338-9"},{"issue":"18","key":"10.1016\/j.ctrv.2025.103083_b0485","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013Drug Conjugates (ADCs): current and future biopharmaceuticals","volume":"30","author":"Wang","year":"2025","journal-title":"J Hematol Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225002051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225002051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:58:20Z","timestamp":1770479900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225002051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":100,"alternative-id":["S0305737225002051"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103083","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103083"}}